Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression

Medicine and Dentistry

• Programmed Death-Ligand 1 100%
• Cyclic AMP 41%
• Immunosuppressive Drug 25%
• Immune Checkpoint Blockade 16%
• Interleukin-6 16%
• Neoplasm 8%
• Cell Surface 8%
• Protein Expression 8%
• Lymphocyte 8%
• Lymphoma 8%
• Secretion (Process) 8%
• Cytokine 8%
• Innate Immunity 8%
• Immunosuppressive Treatment 8%
• Phosphodiesterase 8%
• Diffuse Large B-Cell Lymphoma 8%
• Adaptive Immunity 8%
• Cell Activity 8%
• Clinical Observation 8%
• Phosphodiesterase IV Inhibitor 8%
• Roflumilast 8%
• Regulatory Mechanism 8%
• T Cell 8%
• Human 8%
• Comorbidity 8%

Immunology and Microbiology

• Immunosuppressive Drug 25%
• B Cell 8%
• Syngenic 8%
• Cell Surface 8%
• Secretion (Process) 8%
• Knockout Mouse 8%
• Innate Immune System 8%
• Protein Expression 8%
• Human 8%
• Lymphocyte 8%
• Adaptive Immune System 8%
• Cell Activity 8%
• Roflumilast 8%
• PDE4 Inhibitors 8%
• Regulatory Mechanism 8%
• Immunity 8%
• Immunosuppression 8%